Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr. Reddy's Laboratories Ltd. RDY resulting from allegations that Dr. Reddy's may have issued materially misleading business information to the investing public.
On November 6, 2015, Dr. Reddy's disclosed that it received a warning letter from the U.S. Food and Drug Administration over inadequate quality control procedures at three manufacturing plants in India. On this news, shares of Dr. Reddy's fell $11.75 per share or over 18% to close at $53.5 per share on November 6, 2015, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Dr. Reddy's investors. If you purchased shares of Dr. Reddy's on or before November 5, 2015, please visit the firm's website at http://rosenlegal.com/cases-776.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151109006756/en/
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The
Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New
York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax:
(212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.